Cleveland Clinic Lerner Research Institute Logo
Cleveland Clinic Lerner Research Institute Logo
  • About
  • Science
    • Laboratories
    • Office of Research Development
    • Clinical & Translational Research
      Participating in Research
    • Departments
      Biomedical Engineering Cancer Biology Cardiovascular & Metabolic Sciences Florida Research & Innovation Center Genomic Medicine Immunotherapy & Precision Immuno-Oncology
      Infection Biology Inflammation & Immunity Neurosciences Ophthalmic Research Quantitative Health Sciences Translational Hematology & Oncology Research
    • Centers & Programs
      Advanced Musculoskeletal Imaging Angiogenesis Center Cardiovascular Diagnostics & Prevention Computational Life Sciences Consortium for Pain Genitourinary Malignancies Research Genome Center
      Microbiome & Human Health Musculoskeletal Research Northern Ohio Alcohol Center Pathogen & Human Health Research Populations Health Research Quantitative Metabolic Research Therapeutics Discovery
  • Core Services
    • Ohio
      3D Printing Bioimage AnalysisBioRobotics & Mechanical Testing Cell Culture Cleveland Clinic BioRepository Computational Oncology Platform Computing Services Discovery Lab Electron Microscopy Electronics Engineering
      Flow CytometryGenomic Medicine Institute Biorepository Genomics Glassware Histology Hybridoma Immunohistochemistry Immunomonitoring Lab Instrument Refurbishing & Repair Laboratory Diagnostic
      Lerner Research Institute BioRepository Light MicroscopyMechanical Prototyping Microbial Culturing & Engineering Microbial Sequencing & Analytics Resources Media Preparation Molecular Biotechnology Nitinol Polymer Proteomics & Metabolomics Therapeutics Discovery
    • Florida
      Bioinformatics
      Flow Cytometry
      Imaging
  • Education & Training
    • Graduate Programs Molecular Medicine PhD Program Postdoctoral Program
      Research Intensive Summer Experience (RISE) Undergraduate & High School Programs
  • News
  • Careers
    • Faculty Positions Research Associate & Project Staff Postdoctoral Positions Technical & Administrative Engagement & Belonging
  • Donate
  • Contact
  • About
  • Science
    • Scientific Programs
    • Laboratories
    • Office of Research Development
    • Clinical & Translational Research
      Participating in Research
    • Departments
      Biomedical Engineering Cancer Biology Cardiovascular & Metabolic Sciences Florida Research & Innovation Center Genomic Medicine Immunotherapy & Precision Immuno-Oncology
      Infection Biology Inflammation & Immunity Neurosciences Ophthalmic Research Quantitative Health Sciences Translational Hematology & Oncology Research
    • Centers & Programs
      Advanced Musculoskeletal Imaging Angiogenesis Center Cardiovascular Diagnostics & Prevention Computational Life Sciences Consortium for Pain Genitourinary Malignancies Research Genome Center
      Microbiome & Human Health Musculoskeletal Research Northern Ohio Alcohol Center Pathogen & Human Health Research Populations Health Research Quantitative Metabolic Research Therapeutics Discovery
  • Core Services
    • All Cores
    • Ohio
      3D Printing Bioimage Analysis BioRobotics & Mechanical Testing Cell Culture Cleveland Clinic BioRepository Computational Oncology Platform Computing Services Discovery Lab Electron Microscopy Electronics Engineering >
      Flow CytometryGenomic Medicine Institute BiorepositoryGenomics Glassware Histology Hybridoma Immunohistochemistry Immunomonitoring Lab Instrument Refurbishing & Repair Laboratory Diagnostic
      Lerner Research Institute BioRepository Light MicroscopyMechanical Prototyping Microbial Culturing & Engineering Microbial Sequencing & Analytics Resources Media Preparation Molecular Biotechnology Nitinol Polymer Proteomics & Metabolomics Therapeutics Discovery
    • Florida
      Bioinformatics
      Flow Cytometry
      Imaging
  • Education & Training
    • Research Education & Training Center
    • Graduate Programs Molecular Medicine PhD Program Postdoctoral Program
      Research Intensive Summer Experience (RISE) Undergraduate & High School Programs
  • News
  • Careers
    • Faculty Positions Research Associate & Project Staff Postdoctoral Positions Technical & AdministrativeEngagement & Belonging
  • Donate
  • Contact
  • Search

Research News

❮News Interrupting cancer stem cell renewal promising in combatting glioblastoma

03/03/2023

Interrupting cancer stem cell renewal promising in combatting glioblastoma

Targeting the protein WRD5 could break down the functions of cancer stem cells that allow them to resist treatment.

Above: Glioblastoma organoids treated with the WDR5 inhibitor, showing dramatic loss of proliferating cells including stem cells, and overall decrease in cancer growth (Photo courtesy of: Christopher Hubert, PhD)

Researchers at Cleveland Clinic are finding more effective treatments for glioblastoma, the most common type of malignant brain tumor found in adults for which no cure currently exists.

The research focuses on targeting cancer stem cells – a population of cells inside a tumor that repopulate indefinitely and are extremely treatment-resistant.

In a paper published in Genes & Development, the investigators identified the protein WRD5 as a promising way to turn off cancer “stemness” at a molecular level, clearing the way for treatment like chemotherapy to kill glioblastoma cells. Cancer stem cells, like regular stem cells, are able to inherently repair damaged DNA and divide into different cell types. Regular stem cells repopulate healthy tissue, but cancer stem cells repair tumors after cancer treatment.

“A drug targeting WRD5 would disrupt cancer stem cells’ epigenetic state – meaning the cells wouldn’t be able to grow or multiply in the way that helps them resist treatment,” says Justin Lathia, PhD, Cardiovascular & Metabolic Sciences and the Melvin H. Burkhardt Endowed Chair for Neuro-Oncology Clinical Research.

The study combined expertise in cancer stem cell biology and drug development, a collaboration between the Lathia Lab, Shaun Stauffer, PhD, Director of the Center for Therapeutics Discovery, and Christopher Hubert, PhD, formerly of Cardiovascular & Metabolic Sciences and now an Assistant Professor at the Case Comprehensive Cancer Center. Kelly Mitchell, PhD, a former post-doctoral fellow, is the first author on the study.

The study defined WRD5’s role by using organoids, three-dimensional tissue cultures used to study complex structures like tumors. When using organoids, researchers can look at how a certain drug affects the multiple types of cells that make up a tumor as opposed to conventional cell culture approaches. When existing drugs that inhibit WRD5 were introduced in preclinical models, the inhibitors disrupted cancer stem cell growth and self-renewal, preventing tumors from re-growing.

Targeting WRD5 – and other proteins associated with glioblastoma cancer stem cell survival – requires developing drugs that can breach the blood-brain barrier. The blood-brain barrier is an immune response that protects the brain from viruses or pathogens, acting as a gatekeeper between the bloodstream and the brain. Tumors in the brain can exploit this defense, making their own “blood-tumor” barriers and limiting therapeutics.

Dr. Stauffer’s lab specializes in small-molecule therapeutics development, using compounds and molecular features with low molecular weights to elude these gatekeepers and enter cells more easily. Now that WDR5 is known to elicit a vulnerability in glioblastoma stem cells, the challenge is designing a tool that can reach and kill the tumors, Dr. Stauffer says. To test the drugs, researchers can use a model of the inside of the skull that has intact blood-brain and blood-tumor barriers.

 “We’re getting closer to the ‘holy grail’ of glioblastoma treatment – being able to navigate this response and then attack tumors without damaging any healthy cells in the brain,” Dr. Lathia says. “Luckily, having experts that can tackle this comprehensively is bringing us forward in addressing this problem.”

Featured Experts
Justin Lathia Headshot
Justin
Lathia, PhD
Shaun Stauffer Headshot
Shaun
Stauffer, PhD
News Category
news
Related News
Researchers Find New Cancer Stem Cell-Related Target for Treating GlioblastomaTargeting WISP1 Shows Early Promise in Treating Glioblastoma in Preclinical ModelNIH Funds Collaborative Study into Mechanisms of Glioblastoma Treatment Resistance

Research areas

Cardiovascular & Metabolic Sciences

Want To Support Ground-Breaking Research at Cleveland Clinic?

Discover how you can help Cleveland Clinic save lives and continue to lead the transformation of healthcare.

Give to Cleveland Clinic

Subscribe to get the latest research news in your inbox.

About Lerner

About Us Careers Contact Us Donate People Directory

Science

Clinical & Translational Research Core Services Departments, Centers & Programs Laboratories Research News

Education & Training

Graduate Programs Molecular Medicine PhD Program Postdoctoral Program RISE Program Undergraduate & High School Programs

Site Information & Policies

Search Site Site Map Privacy Policy Social Media Policy

9500 Euclid Avenue, Cleveland, Ohio 44195 | © 2025 Lerner Research Institute